WS®1442 in Slightly Overweight Subjects

• Status: Completed
• Trial end date: 2011-02-01

Summary

The purpose of this study is to test:

1. Safety of 900 mg or 1800 mg of WS® 1442 per day in overweight subjects (BMI 25 to 29,9 kg/m²)

2. Pharmacodynamic effect of WS® 1442 on endothelial function versus nordic walking training in overweight subjects

• Phase: Phase 1

Details

• Lead Sponsor: Dr. Willmar Schwabe GmbH & Co. KG